BETA BIONICS is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPNEW YORK, NY - January 17, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (
NASDAQ: BBNX).
BETA BIONICS is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Investors of Beta Bionics, Inc. (BBNX) to an Investigation of Possible Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Investors of Beta Bionics, Inc. (BBNX) to an Investigation of Possible Securities Law ViolationsNEW YORK, NY - January 16, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (
NASDAQ: BBNX).
Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2025 performance.
Kaplan Fox is Investigating Beta Bionics, Inc. (BBNX) for Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox is Investigating Beta Bionics, Inc. (BBNX) for Potential Securities Law ViolationsNEW YORK, NY - January 15, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (
NASDAQ: BBNX).
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law FirmLOS ANGELES, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (
NASDAQ: BBNX) for violations of the securities laws.
Kaplan Fox Announces an Investigation Into Beta Bionics, Inc. (BBNX) for Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Announces an Investigation Into Beta Bionics, Inc. (BBNX) for Potential Securities Law ViolationsNEW YORK, NY - January 14, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (
NASDAQ: BBNX).
Kaplan Fox & Kilsheimer LLP is Investigating Beta Bionics, Inc. (BBNX) for Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox & Kilsheimer LLP is Investigating Beta Bionics, Inc. (BBNX) for Potential Securities Law ViolationsNEW YORK, NY - January 13, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (
NASDAQ: BBNX).
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (
NASDAQ: BBNX).
Securities Fraud Investigation Into Beta Bionics, Inc. (BBNX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (
NASDAQ: BBNX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – BBNX
The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (
NASDAQ: BBNX) for violations of the securities laws.
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (
NASDAQ: BBNX) for violations of the securities laws.
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key MetricsIRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025.
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026.
Beta Bionics Announces Participation at Upcoming Investor ConferencesIRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time):
